Should I buy or sell ANI Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks .

What is ANI Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 12-month price objectives for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $83.00. On average, they predict the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts .

How have ANIP shares performed in 2024?

ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of 2024. Since then, ANIP stock has increased by 18.8% and is now trading at $65.48. View the best growth stocks for 2024 here .

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 197,000 shares, a decrease of 24.7% from the March 15th total of 261,600 shares. Based on an average trading volume of 137,600 shares, the short-interest ratio is presently 1.4 days. View ANI Pharmaceuticals' Short Interest .

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ANIP earnings forecast .

How can I listen to ANI Pharmaceuticals' earnings call?

ANI Pharmaceuticals will be holding an earnings conference call on Friday, May 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-938-2239 with passcode "4555224".

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The specialty pharmaceutical company earned $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 18.06% and a net margin of 3.86%.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP) , Invesco S&P SmallCap Health Care ETF (PSCH) , Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of 4.260-4.670 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $534.2 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com . Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS) , Gilead Sciences (gild) , Micron Technology (MU) , AbbVie (ABBV) , Teva Pharmaceutical Industries (TEVA) , Alibaba Group (BABA) , Broadcom (AVGO) , Cisco Systems (CSCO) , Exelixis (EXEL) and Intel (INTC) .

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.12%), Allspring Global Investments Holdings LLC (0.10%), State of Alaska Department of Revenue (0.04%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma , Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh , Stephen P Carey and Thomas Haughey . View institutional ownership trends .

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ANIP Stock Alerts

$65.48

+0.90 (+1.39%)

(As of 04/19/2024 ET)

Compare

Today's Range: $64.20
▼
$65.74
50-Day Range: $55.02
▼
$69.69
52-Week Range: $36.99
▼
$70.81

Volume: 207,268 shs
Average Volume: 139,655 shs
Market Capitalization: $1.38 billion

P/E Ratio: 77.95
Dividend Yield: N/A
Price Target: $80.00

Get ANI Pharmaceuticals alerts:

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 22.2% Upside
$80.00 Price Target
Short Interest: Healthy
0.93% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.48
Upright™ Environmental Score
News Sentiment: 0.42
Based on 12 Articles This Week
Insider Trading: Selling Shares
$9.59 M Sold Last Quarter
Proj. Earnings Growth: 16.62%
From $3.55 to $4.14 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

58th out of 912 stocks

Pharmaceutical Preparations Industry

19th out of 420 stocks

2.5

Analyst's Opinion

Consensus Rating
ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.93% of the outstanding shares of ANI Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
ANI Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ANI Pharmaceuticals has recently decreased by 24.69%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ANI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ANI Pharmaceuticals does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.
Environmental Sustainability
The Environmental Impact score for ANI Pharmaceuticals is -2.48.

2.5

News and Social Media Coverage

News Sentiment
ANI Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for ANI Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
8 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,586,490.00 in company stock.
Percentage Held by Insiders
12.70% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for ANI Pharmaceuticals are expected to grow by 16.62% in the coming year, from $3.55 to $4.14 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ANI Pharmaceuticals is 77.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.18.
Price to Earnings Ratio vs. Sector
The P/E ratio of ANI Pharmaceuticals is 77.95, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 177.41.
Price to Book Value per Share Ratio
ANI Pharmaceuticals has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANIP Stock News Headlines

April 18, 2024 | insidertrades.com

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 Shares

April 16, 2024 | insidertrades.com

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $16,947.50 in Stock

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 3, 2024 | insidertrades.com

Chad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

April 19, 2024 | americanbankingnews.com

Muthusamy Shanmugam Sells 7,414 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

April 19, 2024 | americanbankingnews.com

Muthusamy Shanmugam Sells 9,520 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

April 19, 2024 | investing.com

Ani Pharmaceuticals executive sells over $1.5 million in company stock

April 18, 2024 | globenewswire.com

ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | americanbankingnews.com

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares

April 12, 2024 | finance.yahoo.com

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is favoured by institutional owners who hold 64% of the company

April 10, 2024 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know

April 10, 2024 | stocknews.com

3 Biotech Stocks Gaining Altitude and Interest

April 9, 2024 | finanznachrichten.de

ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

April 9, 2024 | globenewswire.com

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

April 4, 2024 | globenewswire.com

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

April 3, 2024 | globenewswire.com

ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium

April 2, 2024 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know

March 27, 2024 | globenewswire.com

ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP

March 23, 2024 | finance.yahoo.com

NYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist Investors

March 21, 2024 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

March 19, 2024 | money.usnews.com

ANI Pharmaceuticals Inc

March 14, 2024 | stocknews.com

3 Biotech Stocks to Jumpstart Your Portfolio Gains

March 12, 2024 | benzinga.com

ANI Pharmaceuticals SVP & CFO Sold $510K In Company Stock

March 9, 2024 | finance.yahoo.com

ANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 Shares

March 7, 2024 | finance.yahoo.com

Director Antonio Pera Sells 7,000 Shares of ANI Pharmaceuticals Inc (ANIP)

March 6, 2024 | markets.businessinsider.com

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts

See More Headlines

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANIP
Previous Symbol: NASDAQ:BPAX
CUSIP: N/A
CIK: 1023024
Web: www.anipharmaceuticals.com
Phone: (218) 634-3500
Fax: 218-634-3540
Employees: 642
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $80.00
High Stock Price Target: $83.00
Low Stock Price Target: $77.00
Potential Upside/Downside: +22.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.84
Trailing P/E Ratio: 77.95
Forward P/E Ratio: 18.45
P/E Growth: N/A
Net Income: $18.78 million
Net Margins: 3.86%
Pretax Margin: 4.08%
Return on Equity: 18.06%
Return on Assets: 8.38%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 3.57
Quick Ratio: 2.81

Sales & Book Value

Annual Sales: $486.82 million
Price / Sales: 2.84
Cash Flow: $6.42 per share
Price / Cash Flow: 10.20
Book Value: $21.13 per share
Price / Book: 3.10

Miscellaneous

Outstanding Shares: 21,079,000
Free Float: 18,402,000
Market Cap: $1.38 billion
Optionable: Optionable
Beta: 0.79

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Nikhil Lalwani (Age 46)
President, CEO & Director
Comp: $1.31M
Mr. Stephen P. Carey (Age 53)
Senior VP of Finance & CFO
Comp: $751k
Mr. James G. Marken (Age 61)
Senior Vice President of Operations & Product Development
Comp: $673.23k
Mr. Muthusamy Shanmugam MS R.Ph. (Age 56)
Head of R&D, COO of Novitium Operations & Director
Mr. Chad Gassert (Age 48)
Senior Vice President of Corporate Development & Strategy
Ms. Elizabeth Powell J.D.
Chief Compliance Officer & Head of Legal of Rare Disease
Dr. Mary Pao M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.
What is ANI Pharmaceuticals' stock price target for 2024?: 4 Wall Street research analysts have issued 12-month price objectives for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $83.00. On average, they predict the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.
How have ANIP shares performed in 2024?: ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of 2024. Since then, ANIP stock has increased by 18.8% and is now trading at $65.48.
View the best growth stocks for 2024 here.
Are investors shorting ANI Pharmaceuticals?: ANI Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 197,000 shares, a decrease of 24.7% from the March 15th total of 261,600 shares. Based on an average trading volume of 137,600 shares, the short-interest ratio is presently 1.4 days.
View ANI Pharmaceuticals' Short Interest.
When is ANI Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ANIP earnings forecast.
How can I listen to ANI Pharmaceuticals' earnings call?: ANI Pharmaceuticals will be holding an earnings conference call on Friday, May 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-938-2239 with passcode "4555224".
How were ANI Pharmaceuticals' earnings last quarter?: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The specialty pharmaceutical company earned $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 18.06% and a net margin of 3.86%.

What ETFs hold ANI Pharmaceuticals' stock?: ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?: ANI Pharmaceuticals updated its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of 4.260-4.670 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $534.2 million.
What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?: 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.
What other stocks do shareholders of ANI Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).
Who are ANI Pharmaceuticals' major shareholders?: ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.12%), Allspring Global Investments Holdings LLC (0.10%), State of Alaska Department of Revenue (0.04%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey.
View institutional ownership trends.
How do I buy shares of ANI Pharmaceuticals?: Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial